Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Section 3 of 6

Product information and disease description

434 evidence topics · 165 sources

Product description

Phase of product development

Regulatory status: Under review; NDA accepted July 2026, PDUFA target action date April 2027
Development history: RAPIDe-3 initiation, enrollment, and topline results
FDA clinical hold, August 2022, and its lifts in June 2023 and January 2024
EU paediatric investigation plan, agreed October 2023 and modified January 2025
FDA expedited program designations

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Brand name

No evidence found.

Dosage forms and strengths
Material safety data sheet

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS classification

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Single ascending doses of oral solution in healthy volunteers: pharmacokinetic parameters
Parameter1 mg fasted2 mg fasted4.5 mg fasted12 mg fasted22 mg fasted22 mg after high-calorie, high-fat breakfast
Cmax, ng/mL, mean (SD)“11.1 (4.03)”“19.8 (3.70)”“32.9 (7.66)”“97.3 (28.1)”“213 (49.5)”“145 (56.2)”
AUClast, ng.h/mL, mean (SD)“33.0 (25.9)”“66.0 (27.0)”“129 (56.5)”“369 (194)”“681 (113)”“1015 (490)”
t1/2, h, mean (SD)“3.49 (1.32)”“4.26 (1.91)”“4.36 (1.29)”“4.25 (0.831)”“5.61 (0.707)”“5.31 (1.54)”
CL/F, L/h, mean (SD)“42.3 (25.4)”“33.8 (11.9)”“37.6 (11.1)”“40.9 (20.7)”“31.5 (5.60)”“25.3 (9.77)”
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information for deucrictibant

Not applicable.

Special populations
Older adults: upper age limit and participants aged 65 years or older in the phase 3 trial
Age groupRAPIDe-3 enrolled participants (N = 134), n (%)
Aged 12 to younger than 18 years“10 (7.5)”
Aged 18 to younger than 65 years“116 (86.6)”
Aged 65 years or older“8 (6.0)”
Drug/Drug, drug/disease interactions
Effects of other drugs on Deucrictibant
Effects of Deucrictibant on other drugs
Dosing and administration
Dosage
Administration
Access and distribution
Expanded access program in the United States (NCT07759141)
Specialty pharmacy or limited distribution arrangements

No evidence found.

Co-prescribed/Concomitant therapies
RAPIDe-3: concomitant long-term prophylaxis permitted
RAPIDe-3: long-term prophylaxis agents used by participants who treated at least one attack
Long-term prophylaxisDeucrictibant (n=101)Placebo (n=100)Overall participants (n=113)
Any concomitant long-term prophylaxis“20 (20%)”“24 (24%)”“26 (23%)”
Lanadelumab“8 (8%)”“10 (10%)”“11 (10%)”
Berotralstat“5 (5%)”“7 (7%)”“7 (6%)”
C1-esterase inhibitor“4 (4%)”“5 (5%)”“5 (4%)”
Danazol“3 (3%)”“2 (2%)”“3 (3%)”
Effect of Deucrictibant on quality measures

No evidence found.

Product comparison
Indirect comparison of recombinant C1 esterase inhibitor with sebetralstat funded by Pharming

“In the primary analysis, rhC1-INH was associated with a statistically significant 4.5-fold increased likelihood of achieving complete resolution (HR 4.52; 95% CI 2.84–7.18) and a significant 82% reduction in redosing (OR 0.18; 95% CI 0.06–0.53) vs sebetralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All patients in the rhC1-INH trials had a severe or very severe attack at baseline based on the PGI-S scale [3, 4], whereas patients enrolled in the KONFIDENT trial had a range of baseline attack severities, with only 17.5% of patients having severe or very severe attacks at baseline [8].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The rhC1-INH trials required clinic visits for assessment and treatment, resulting in delayed rhC1-INH administration (median 242 min) [3, 4], whereas the KONFIDENT trial allowed for self-administration of sebetralstat (median 41 min) [8].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In these scenario analyses, the HRs for TTCR were 1.41 (95% CI 0.63–3.18) and 9.76 (95% CI 4.94–19.29).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Rapid Service and Open Access fees were funded by Pharming Healthcare, Inc., Warren, NJ, USA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Place of product in therapy

Disease description

Definition and etiology
Epidemiology
Incidence of hereditary angioedema
Prevalence of hereditary angioedema
Pooled diagnosed annual prevalence: combined HAE types and 95% confidence interval
Natural history, survival, and mortality
Pathophysiology
Diagnosis
Clinical presentation - signs and symptoms
Laryngeal symptoms: frequency, age at first episode, and time to maximum swelling in 123 patients
Attack site and duration with and without on-demand treatment: Milan angioedema centre, 2014
Long-term morbidity
Burden of hereditary angioedema
Humanistic burden and health-related quality of life
Multinational adult survey: treatment exposure and quality-of-life outcomes
MeasureReported result
Participants included“260”
Participants using any long-term prophylaxis“153 (58.8%)”
First-line prophylaxis among prophylaxis users, per study classification“56/153 (36.6%)”
AE-QoL total score, mean ± SD“42.9 ± 23.2”
Participants with AE-QoL total score ≥39“137 of 260 (52.7%)”
Moderate to severe anxiety by HADS“69 (26.5%)”
Moderate to severe depression by HADS“27 (10.4%)”
Health-related quality of life during the last treated attack by time to on-demand treatment: US patient survey

“Patients with ≥1 HAE attack in the previous 3 months were recruited by the United States (US) HAE Association (HAEA) to complete an online survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 94 respondents were included in the Treated Cohort, and 20 were included in the Untreated Cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the Treated Cohort, the mean (SD) EQ-5D-5L index score was 0.849 (0.2) “Today” and 0.568 (0.3) “During the last treated attack” (Fig. 1A), with the latter score indicative of substantial impairment in HRQoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The mean (SD) index score was 0.667 (0.3) in patients who treated <1 h of attack onset and 0.504 (0.3) in those who treated 5 to < 8 h of attack onset (Fig. 1B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In terms of administration route, reductions in HRQoL and work productivity and increases in activity impairment were generally more pronounced among IV OD users than among SC OD users (mean EQ-5D-5L index score “During the last treated attack”: 0.480 vs 0.615).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Consistent with this, IV OD users took longer to administer treatment following attack onset than SC OD users (mean: 5.8 vs 2.8 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Funding for Outcomes Insights was provided by KalVista Pharmaceuticals (Cambridge, MA, USA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Burden of injectable on-demand treatment: US and UK patient and caregiver interviews
Carrying, delaying, and not treating attacks with on-demand treatment: US patient survey

“People living with HAE were recruited by the US Hereditary Angioedema Association (HAEA) to complete a 20-minute online survey between September 6, and October 19, 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Respondents included 107 people with HAE, 80% female, 98% adults (≥ 18 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Most patients (63.6%) reported that they did not carry on-demand treatment at all times when away from home.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most common reason for not carrying on-demand treatment when away from home was ‘prefer to treat at home’ (72.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, 86% of respondents reported delaying on-demand treatment, despite recognizing the initial onset of an HAE attack and despite 97% of patients agreeing that it is important to recover quickly from an HAE attack.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“On average, one of every five (20%) HAE attacks are untreated (24% amongst on-demand only patients; 15% amongst prophylaxis patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This work was sponsored by KalVista Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Attacks, on-demand treatment, anxiety, and depression: multinational patient survey
Economic burden and healthcare resource utilization
Cost per attack treated on demand: Italian prospective cohort

“To explore treatment behaviours in a cohort of Italian patients with hereditary angioedema due to complement C1-inhibitor deficiency (C1-INH-HAE), and to estimate how effects and costs of treating attacks in routine practice differed across available on-demand treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Cost analyses and survival analyses using attack-level data collected prospectively for 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, 133 of 167 patients (79.6%) reported 1508 attacks during the study period, with mean incidence of 11 attacks per patient per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Only 78.9% of attacks were treated in contrast to current guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The average cost per attack was €1183 (SD €789) resulting in €1.58 million healthcare costs during the observation period (€11 912 per patient per year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Icatibant was 54% more expensive than pdC1-INH, whereas age, sex and prophylactic treatment were not associated to higher or lower costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Emergency department and hospital use among users of intravenous C1 inhibitor: US claims

“The purpose of this retrospective study was to evaluate real-world treatment patterns of HAE-specific medications in the US and to assess their impact on healthcare resource utilization (HCRU).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This analysis used IMS PharMetrics PlusTM database records (2006–2014) of patients with HAE, ≥1 insurance claim for an HAE-specific medication, and continuous insurance enrollment for ≥3 months following the first HAE prescription claim.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of 631 total patients, 434 (68.8%) reported C1-INH(IV) use; 396 (62.8%) reported using ecallantide and/or icatibant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There were 306 episodes of prophylactic use of C1-INH(IV) (defined by continuous refills averaging ≥1500 IU/week for ≥13 weeks) in 155 patients; use of ≥1 on-demand rescue medication was implicated during 53% (163/306) of those episodes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Sixty-eight (20.2%) of 336 C1-INH(IV) users eligible for the HCRU analysis were hospitalized at least once, and 191 (56.8%) visited the emergency department (ED).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This study was funded by CSL Behring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Hospitalizations and emergency department visits with hereditary angioedema: nationally representative inpatient and emergency department samples, 2007
Attack-related medical visits and provider-administered on-demand treatment before and after berotralstat: US claims

“To evaluate all-cause, angioedema-related, and HAE attack–related medical visits and hospitalizations before and after initiation of berotralstat long-term prophylaxis (LTP) for patients with HAE in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This retrospective pre-post analysis used Komodo’s Healthcare Map claims data to identify patients who initiated berotralstat (December 2020 to December 2022).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The study population included 260 patients treated with berotralstat (mean age = 39.7 years; 74.2% female).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“When stratifying by type of care setting, rates of HAE attack–related IP episodes decreased by 60% (from 0.28 to 0.11 PPY, P < 0.001) and OP/ED episodes decreased by 50% (from 1.46 to 0.74 PPY, P < 0.001) after berotralstat initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Following berotralstat initiation, the rates of on-demand medication administered by a provider decreased significantly by 32% (from 1.17 to 0.87 PPY, P = 0.002) among all patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Medical writing assistance was provided by Molly Gingrich, an employee of Groupe d’Analyze, Ltée, which received funding from BioCryst Pharmaceuticals for this study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Medical care, activity loss, and missed work or school: European patient survey

“The study was conducted in Spain, Germany, and Denmark to assess the real-world experience of HAE via a cross-sectional survey of HAE patients, including direct and indirect resource utilization during and between attacks for patients and their caregivers over the past 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, 164 patients had an attack in the past 6 months and were included in the analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most significant predictor of medical resource utilization was the severity of the last attack (OR 2.6; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among patients who sought medical care during the last attack (23%), more than half utilized the emergency department.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The last attack prevented patients from their normal activities an average of 4–12 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among patients who were working or in school (n = 120), 72 provided work/school absenteeism data, resulting in an estimated 20 days missing from work/school on average per year; 51% (n = 84) indicated that HAE has hindered their career/educational advancement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The study was funded by ViroPharma SPRL-BVBA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Economic impact of hereditary angioedema on families
Caregiver time, missed work, and children's missed school: multinational caregiver survey

“Using web-based surveys (July 2022‒February 2023), this international study (Argentina, Brazil, Colombia, Croatia, Denmark, Germany, Hungary, Ireland, Norway, Poland, Portugal, Romania, and Sweden) assessed the humanistic and psychosocial burden of caregivers (≥ 18 years old) of pediatric (< 18 years) and adult (≥ 18 years) patients with diagnosed HAE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In total, 120 caregivers completed the surveys: 54 caregivers of pediatric patients (CoPs; mean age 40.6 years; 79.6% female) and 66 caregivers of adult patients (CoAs; mean age 42.7 years; 48.5% female).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the 4 weeks before completing the survey, caregivers of pediatric patients reported being absent from work for 2.6 ± 5.8 days (mean ± SD; median, 1.0 day), while the patients in their care missed 3.9 ± 6.2 days of school (mean ± SD; median, 2.0 days) over the same period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Caregivers reported providing care for 23.5 ± 11.8 (mean ± SD) days per month.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Caregivers of pediatric patients reported that their caregiving responsibilities limited their ability to plan their own lives in different ways, notably, to work full time (33.3%), to advance in their professional careers (25.9%), to pursue their personal interests or hobbies (25.9%), their freedom to travel or go on holiday (24.1%), and to relocate to another city or country (9.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the 4 weeks before the survey, caregivers (n = 33) reported missing 0.94 ± 1.39 (mean ± SD) days of work” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“During the patient’s most recent HAE attack, help provided by the caregivers primarily included providing emotional support (72.7%), spending time with the patient (68.2%), help with administering HAE medication (51.5%), and help with household chores (48.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This study was sponsored by Takeda Development Center Americas, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Economic impact of diagnostic testing

Approaches to treatment

Current treatment options and standard of care
C1 esterase inhibitor concentrates
Recombinant human C1 inhibitor 50 U/kg versus placebo: Study 1 in the label
Intravenous C1 inhibitor as a first-line on-demand treatment: guideline recommendations
Bradykinin b2 receptor antagonists
Plasma kallikrein inhibitors for on-demand treatment
Long-term prophylaxis
Fresh frozen plasma and other measures
Upper airway involvement and airway management: guideline recommendations
Limitations of current therapies
Summary: injectable administration, treatment delay, and untreated attacks

The approved on-demand C1 inhibitors are given intravenously (plasma-derived C1 inhibitor at 20 IU/kg by intravenous injection; recombinant C1 inhibitor at 50 U/kg as a slow intravenous injection), icatibant is given as a 30 mg subcutaneous injection, and ecallantide as three 10 mg subcutaneous injections; sebetralstat is taken orally. The sponsor states that most on-demand therapies are administered by injection and that this burden causes people to delay or forgo treatment of their attacks. In interviews with 25 US and UK patients and caregivers, participants cited fear of needles, portability, and complexity of administration as reasons for delaying or forgoing injectable on-demand treatment; 80% reported not treating every attack, and some adult and all adolescent patients reported needing assistance with administration.

In a survey of 107 respondents, 57% did not treat all attacks, only 14% treated attacks immediately, and the mean time to treatment was 2.4 h; respondents who waited 1 h or longer cited the attack not being considered severe enough to treat (86.9%), not having on-demand treatment with them (59%), and the treatment being too painful (32.8%), and 32.7% of respondents experienced the return of an attack after initial treatment. Another report of 107 US survey respondents found that 63.6% did not carry on-demand treatment at all times when away from home, 86% reported delaying on-demand treatment, and an average of 20% of attacks were untreated (24% among on-demand-only patients and 15% among prophylaxis patients). In a further US survey, of the 67% of the treated cohort (n = 94) who reported treating early, only 26% administered on-demand treatment in less than 1 hour, 79% reported treatment-related anxiety that correlated with treatment delay, and untreated attacks lasted a mean of 2.3 days. In a survey funded by KalVista Pharmaceuticals, the mean delay from attack onset to on-demand treatment was 2.9 h (SD 2.7), 10% treated within 1 h, 13% sought hospital or emergency services for administration during the last treated attack, 51% required caregiver support, and adolescents and users of intravenous on-demand treatment were more likely to delay treatment because of administration-related barriers. Patients using long-term prophylaxis reported treating a mean of 84.8% of their attacks, compared with 75.6% for patients using on-demand treatment only. In the Icatibant Outcome Survey, 44% of attacks in self-administrators and 22% in patients receiving icatibant from a health care professional were treated within 1 hour of onset, and attack duration was 6.1 hours in patients treated within 1 hour of onset and 16.8 hours in those treated at 1 hour or later.

Summary: adverse reactions, administration by health care professionals, and restrictions of use

Injection site reactions occurred in 97% of patients receiving icatibant in clinical trials. In FDA Adverse Event Reporting System data for the parenteral on-demand therapies, the highest reported rates of administration-site reactions were site pain (17.9 reports per year), site erythema (7.4 per year), and site swelling (6.7 per year), and access-site complications or malfunctions were reported only for recombinant C1 inhibitor (9.5 per year); these rates are not exposure adjusted. Serious arterial and venous thromboembolic events have been reported with plasma-derived C1 esterase inhibitor products, and plasma-derived C1 inhibitor may carry a risk of transmitting infectious agents. Recombinant C1 inhibitor is contraindicated in patients with allergy to rabbits or rabbit-derived products, and its effectiveness was not established in laryngeal attacks. Anaphylaxis occurred in 10 of 255 participants (4%) treated with ecallantide in clinical studies, and ecallantide is administered only by a health care professional; a guideline suggests it only as a second-line option. Icatibant is indicated for adults 18 years of age and older. Patients who self-administer plasma-derived C1 inhibitor or icatibant for a laryngeal attack are advised to seek medical attention in a health care facility. Plasma products used when HAE-specific treatment is unavailable are available only for in-hospital use, with delays of sometimes up to 24 h in obtaining them.

Users of intravenous C1 inhibitor had higher crude rates of hospitalization (20% vs 6%) and emergency department visits (57% vs 43%) than patients not using an HAE medication requiring intravenous access, and 18 (5.4%) had a central venous access device. Severe laryngeal attacks were not treated in the sebetralstat trial KONFIDENT, and a guideline states that long-term data from extension studies and real-world evidence for sebetralstat are still lacking.

Summary: repeat dosing and rescue medication

Repeat treatment during a single attack is approved for icatibant (up to 3 doses within 24 hours at intervals of at least 6 hours) and for ecallantide and recombinant C1 inhibitor (up to 2 doses within 24 hours); sebetralstat allows a second 600 mg dose at least 3 hours after the first, up to 1,200 mg in any 24-hour period. A guideline states that icatibant more frequently requires a second dose than C1 inhibitor. In Trial 1 of the icatibant label, 3 of 43 participants (7%) treated with icatibant used additional rescue medication, compared with 18 of 45 (40%) with placebo, and in a further analysis in the label, 93% of 987 attacks were treated with a single dose. In the sebetralstat label, 38% of participants in the 600 mg group administered a second dose within 12 hours. Recombinant C1 inhibitor was given as rescue medication to 5 of 44 participants (11%) randomized to it and 13 of 31 (42%) randomized to placebo, and 5 of 170 attacks (3%) in the open-label phase received a second dose. In EDEMA4, 16 of 48 participants (33%) treated with ecallantide and 24 of 48 (50%) given placebo required medical intervention for unresolved symptoms within 24 hours. In the KONFIDENT-S extension, conventional on-demand treatment was administered within 12 h for 3 (9.4%) laryngeal and 43 (8.1%) abdominal attacks treated with sebetralstat.

Summary: attacks and on-demand treatment use during long-term prophylaxis

Guidelines state that long-term prophylaxis does not completely eliminate the risk of attacks and recommend that patients receiving it keep access to on-demand treatment, with at least two doses available. A review of 45 primary studies reported attack-free rates in phase 3 trials of 40% for subcutaneous plasma-derived C1 inhibitor at 16 weeks and 44% for lanadelumab every second week at 6 months, with no difference in attack-free rate for berotralstat versus placebo at 24 weeks; laryngeal attacks accounted for 2% to 7% of attacks, and on-demand therapy was used in 49% to 94% of attacks occurring during prophylaxis. In one claims analysis, on-demand treatment use remained present for over two-thirds of patients after starting prophylaxis, and 55% had refill gaps, discontinued, or switched prophylaxis within a year. Among 196 patients on subcutaneous prophylaxis in another analysis, the mean annualized number of on-demand prescriptions was 3.8 per patient, and in a third, on-demand rescue medication was used during 53% (163/306) of episodes of intravenous C1 inhibitor prophylaxis. In another cohort, patients with at least 12 months on lanadelumab or berotralstat who had an on-demand dispensation were dispensed a mean of 4.3 and 6.5 packages, respectively, in their most recent 12 months, and 22% (15/69) dispensed none. In the KONFIDENT-S extension, 35 participants receiving prophylaxis experienced a mean of 1.7 attacks per month (SD 1.5). A guideline states that only about 50% of patients currently receive long-term prophylaxis, even in high-income countries, and that the higher costs of newer drugs limit their availability.

Untreated attacks, delayed treatment, and attack recurrence: US survey of 107 participants

“A total of 107 out of 155 participants completed the survey (mean age = 41 years; 80.4% female).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The survey revealed that 57% of respondents did not treat all HAE attacks, and only 14% treated attacks immediately.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Delays in treatment were common, with a mean time to treatment of 2.4 h, and younger patients were less likely to carry on-demand treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most important reasons cited by those who waited 1 h or longer to initiate on-demand treatment were the attack not being considered severe enough to treat (86.9%), not having on-demand treatment with them (59%), and their on-demand treatment being too painful (32.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Additionally, 32.7% of respondents experienced the return of an HAE attack after initial treatment, with those delaying treatment more likely to experience recurrence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This work was sponsored by KalVista Pharmaceuticals, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Repeat dosing limits and second-dose frequency with existing on-demand agents
Place in treatment, anticipated use, and care setting
Summary: guideline recommendations for on-demand treatment

The guideline by Vázquez et al. recognizes four types of on-demand treatment as effective (intravenous C1-INH, icatibant, sebetralstat, and ecallantide), recommends intravenous C1-INH, icatibant, or sebetralstat as first-line, suggests ecallantide as a second-line option only when first-line therapies are not available or feasible, and recommends solvent detergent-treated plasma or fresh frozen plasma as third-line; it states that direct comparisons among these options are limited, and recommends intravenous plasma-derived C1-INH as first-line for pregnant patients. The guideline by Betschel et al. lists ecallantide, icatibant, intravenous C1INH, and sebetralstat as effective therapies, discussed “without implying any hierarchy of preference”, and states that access to another effective acute treatment is crucial given variation in patient response. A pediatric guideline recommends icatibant, intravenous plasma-derived C1-INH, or recombinant C1-INH as first-line acute treatment for children aged 2 to 12 years, and ecallantide, icatibant, either intravenous C1-INH, or sebetralstat for adolescents aged 12 years or older.

The guidelines recommend that all attacks be considered for on-demand treatment and treated as early as possible, that every patient have medication for at least 2 attacks, kept at home, and that patients carry on-demand medication at all times; the US HAEA Medical Advisory Board recommends that all patients with HAE due to C1-INH deficiency have access to at least two standard doses. Upper airway swelling calls for on-demand treatment as early as possible and emergency care, and all patients with laryngeal edema are to be assessed in the emergency department even after self-therapy. The Vázquez et al. guideline states that the only oral on-demand treatment available is sebetralstat and that long-term data for it are still lacking. Deucrictibant appears in none of the guidelines' lists of recommended agents; the Vázquez et al. guideline states that preliminary results have demonstrated its efficacy for treating attacks, and the pediatric guideline notes that RAPIDe-3 is evaluating it in adolescent and adult patients.

Summary: anticipated use of an oral on-demand option and care setting

Deucrictibant is described as the first and only orally administered bradykinin B2 receptor antagonist investigated for on-demand treatment of HAE attacks. In RAPIDe-3, participants self-administered the study drug during or immediately after a qualification call with the investigator, and in Part 2 of RAPIDe-1 participants self-administered it at home. Adolescents with laryngeal attacks of any severity and adults with severe laryngeal attacks were instructed to take their conventional on-demand therapy instead of the study drug and to seek medical care urgently. One publication notes that the recommendation to treat all attacks as early as possible shaped the design of recent trials, including those of sebetralstat and deucrictibant.

The trial investigators state that an efficacious oral on-demand option with a favourable safety profile “could address key unmet needs”, and that further studies of patient preferences, including number of pills administered per dose, are warranted. A guideline states that HAE is well suited to self-treatment, especially by oral administration, and that injectable therapies can pose barriers such as needle phobia, poor venous access, or impaired dexterity; ecallantide must be administered under the supervision of health care personnel. The sponsor intends to file for approval of and commercialize deucrictibant immediate-release capsules as an on-demand treatment for HAE attacks through its own commercial infrastructure, states that an oral on-demand treatment could decrease the burden of therapy through easier administration, portability, and discretion, and states its belief that deucrictibant could become standard of care for on-demand treatment. The sponsor is also preparing an NDA for the extended-release tablet for prophylaxis, which reduced the mean monthly attack rate by 83% in CHAPTER-3, with submission planned for 1H2027; these data concern the extended-release tablet.

Summary: patient and physician preference

In a study in which Pharvaris participated in the interpretation of the data, 225 physicians completed patient record forms for 1131 patients and 279 patients completed a questionnaire; 84% of patients in the patient-reported group indicated that, given the choice, they would prefer to take their on-demand treatment by mouth. The top physician-reported unmet needs of on-demand treatment were a different route of administration (320/817 [39%]), discomfort upon administration (112/817 [14%]), and injection site reactions (111/817 [14%]); patients most often reported not liking injections and experiencing pain, bruising, or burning with injections (42/227 [19%] each), followed by not liking to inject medications in public places (38/227 [17%]). In interviews with 25 US and UK patients and caregivers, in a study supported by KalVista Pharmaceuticals, all participants expressed interest in an oral on-demand treatment, and 8 indicated that they would treat attacks earlier with one; more than half regarded the need to swallow a tablet as a potential disadvantage during a throat or facial attack, and some were concerned about how quickly an oral tablet would begin to work.

Summary: payer criteria and quantity limits

Published payer policies refer to generic icatibant in their criteria for on-demand treatment, including sebetralstat (Ekterly). Cigna requires prior authorization, with coverage for patients aged 12 to under 18 years, patients who have previously treated an attack with Ekterly, or patients who have tried generic icatibant; its quantity limits allow treatment of 4 attacks per 28 days at the maximum Ekterly dose, with an override for an additional 4 attacks each month and a one-time override of 16 additional tablets. Univera Healthcare requires documentation of therapeutic failure, severe intolerance, or a contraindication to generic icatibant for Ekterly requests in patients 18 years of age and older, lists a quantity limit of 4 tablets per 30 days, authorizes one acute HAE medication at one time, and does not approve requests for quantities in excess of its limits. A Regence policy requires documentation that generic icatibant and either Berinert or Ruconest have been ineffective, not tolerated, or contraindicated, authorizes acute treatments in a quantity sufficient for three attacks per month, or four to six attacks per month when its criteria are met (including, for HAE types I and II, evaluation for prophylactic therapy), and states that “Generic icatibant is the lowest cost of all available options.”

On-demand medication at home for at least two attacks: guideline recommendations
Company statements on intended positioning
Heterogeneity of treatment effect
RAPIDe-3 regional subgroups: median times to onset of symptom relief, reduction in attack severity, and complete resolution
Outcome and regionDeucrictibant IRPlacebo
Onset of symptom relief, North America“1.20 hours (95% CI: 0.84, 1.84)”“6.55 hours (95% CI: 1.88, >12)”
Onset of symptom relief, Europe/Rest of World“1.28 hours (95% CI: 1.04, 1.41)”“>12 hours (95% CI: 5.74, >12)”
Reduction in attack severity, North America“2.43 hours (95% CI: 1.03, 5.12)”“>12 hours (95% CI: 2.65, >12)”
Reduction in attack severity, Europe/Rest of World“2.53 hours (95% CI: 1.70, 2.98)”“>12 hours (95% CI: 12.10, >12)”
Complete symptom resolution, North America“11.61 hours (95% CI: 2.94, 26.14)”“>48 hours (95% CI: 17.21, >48)”
Complete symptom resolution, Europe/Rest of World“12.04 hours (95% CI: 8.64, 21.79)”“>48 hours (95% CI: >48, >48)”
Sebetralstat open-label extension: attacks during long-term prophylaxis by severity, location, and age

“In subgroup analyses by attack severity at the time of sebetralstat administration, median (IQR) times to beginning of symptom relief in participants receiving any LTP agent were 1.8 (1.0-7.0) hours, 1.3 (0.8-3.5) hours, and 1.3 (0.5-1.8) hours for mild, moderate, and severe/very severe attacks, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Subgroup analyses by attack location showed median (IQR) times to beginning of symptom relief in participants receiving any LTP agent of 1.3 (0.7-2.2) hours, 1.4 (0.9-4.1) hours, 1.0 (0.5-2.2), and 1.7 (1.2-6.0) hours for attacks with mucosal involvement, attacks with laryngeal involvement, attacks limited to the abdomen, and attacks limited to subcutaneous tissues, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In subgroup analyses by age, median (IQR) times to beginning of symptom relief in participants receiving any LTP agent were 0.7 (0.3-1.4) hours and 1.7 (1.1-5.5) hours for participants aged <18 years (n = 5) and participants aged ≥18 years (n = 30), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Furthermore, the study was not designed or powered to evaluate differences in the effectiveness of sebetralstat by the specific LTP agent received or differences between subgroups; these data are reported to offer a preliminary clinical overview.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy